---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-231557"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2023-09-08T23:59:59+00:00"
generated_at: "2026-06-10T22:08:24.369615+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tempest Therapeutics receives Nasdaq bid price deficiency notice, 180 days to comply

## Summary
- Nasdaq notified TPST on Sept 6, 2023 that bid price closed below $1.00 for 30 consecutive days.
- Company has 180 calendar days, until March 4, 2024, to regain compliance.
- To comply, closing bid must be at least $1.00 for a minimum of ten consecutive business days.
- If not compliant by March 4, 2024, TPST may seek an additional 180-day period if eligible.
- Company states it will monitor bid price and evaluate options, including a reverse stock split.

## SEC filing metadata
- accession: 0001193125-23-231557
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2023-09-08T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312523231557/0001193125-23-231557-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312523231557/d532614d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-231557
- JSON: https://secwatch.observer/filing/0001193125-23-231557.json
- Plain text: https://secwatch.observer/filing/0001193125-23-231557.txt

## Key facts
- Listing & Compliance Notices
  Tempest Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: September 6, 2023, Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company’s common stock on the Nasdaq Stock Market. In accordance with
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312523231557/0001193125-23-231557-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.